Enterprise Trust & Investment Co Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)


Share on StockTwits

Enterprise Trust & Investment Co increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 298.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,975 shares of the pharmaceutical company’s stock after purchasing an additional 5,975 shares during the period. Enterprise Trust & Investment Co’s holdings in Vertex Pharmaceuticals were worth $1,829,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Mirova grew its stake in Vertex Pharmaceuticals by 94.1% during the third quarter. Mirova now owns 99 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 48 shares in the last quarter. Newfound Research LLC purchased a new position in Vertex Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Norway Savings Bank purchased a new position in Vertex Pharmaceuticals during the 3rd quarter valued at approximately $39,000. Hexagon Capital Partners LLC bought a new stake in Vertex Pharmaceuticals in the 3rd quarter worth approximately $45,000. Finally, Glassman Wealth Services grew its holdings in shares of Vertex Pharmaceuticals by 38.7% in the third quarter. Glassman Wealth Services now owns 172 shares of the pharmaceutical company’s stock valued at $47,000 after purchasing an additional 48 shares in the last quarter. 92.17% of the stock is owned by institutional investors.

In related news, Director Bruce I. Sachs purchased 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The stock was purchased at an average price of $217.36 per share, with a total value of $3,260,400.00. Following the completion of the acquisition, the director now owns 18,035 shares in the company, valued at $3,920,087.60. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Stuart A. Arbuckle sold 1,553 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $211.92, for a total value of $329,111.76. Following the transaction, the executive vice president now owns 36,732 shares in the company, valued at approximately $7,784,245.44. The disclosure for this sale can be found here. Company insiders own 0.70% of the company’s stock.

Shares of NASDAQ:VRTX opened at $227.10 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.72 and a quick ratio of 3.60. Vertex Pharmaceuticals Incorporated has a 1 year low of $197.47 and a 1 year high of $306.08. The firm has a market capitalization of $59.05 billion, a PE ratio of 28.67, a P/E/G ratio of 1.25 and a beta of 0.79. The business’s 50 day moving average price is $230.82 and its 200-day moving average price is $251.89.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, October 29th. The pharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.68. Vertex Pharmaceuticals had a net margin of 38.51% and a return on equity of 28.55%. The company had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.48 billion. During the same quarter in the previous year, the company posted $1.23 EPS. The firm’s quarterly revenue was up 61.9% on a year-over-year basis. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post 8.5 earnings per share for the current year.

A number of research firms recently issued reports on VRTX. SVB Leerink decreased their price target on shares of Vertex Pharmaceuticals from $267.00 to $257.00 and set a “market perform” rating on the stock in a research note on Friday, October 30th. Royal Bank of Canada upgraded shares of Vertex Pharmaceuticals from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $247.00 to $267.00 in a research report on Monday, November 30th. BidaskClub lowered Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, January 7th. UBS Group started coverage on Vertex Pharmaceuticals in a research report on Wednesday, October 28th. They set a “buy” rating and a $287.00 price objective on the stock. Finally, Daiwa Capital Markets assumed coverage on Vertex Pharmaceuticals in a report on Wednesday, December 30th. They issued an “outperform” rating and a $250.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $289.66.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene.

Featured Article: Are we seeing the beginning of a new bubble?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.